Showing results (431-440 of 649) with videos related to

Sort By:
Pageof 65
Hemasphere|May 6, 2021
Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm ModelsTitiksha Basu, Hannah Bertrand, Nikolaos Karantzelis, et al.
Hemasphere|August 16, 2021
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative NeoplasmsAntonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, et al.
Hemasphere|December 10, 2025
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statementAdam Lamble, Sandra D Bohling, Kara L Davis, et al.
Hemasphere|November 27, 2025
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemiaHaley Newman, Derek Wong, Jinhua Wu, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 12, 2026
Navigating the evolving management of smoldering multiple myelomaM Bakri Hammami, Rafael R Canevarolo, Ariosto S Silva, et al.
Hemasphere|January 21, 2026
Triplet regimens for frontline treatment of CLL-Great company or just a crowd?Sean McKeague, John F Seymour
Hemasphere|January 15, 2026
Tet2 deficiency promotes IgG1+ B-cell expansion and differentiation blockade through deregulation of the Nfkbia-c-Rel axisHussein Ghamlouch, Michaël Degaud, Veronique Della-Valle, et al.
Hemasphere|January 14, 2026
MeMAGEN: A Phase IIa/IIb open-label trial of memantine testing safety and tolerability in sickle cell patientsAriel Koren, Carina Levin, Leonid Livshits, et al.
Hemasphere|January 23, 2026
Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesisSara El Hoss, Maria A Lizarralde-Iragorri, Thiago Trovati Maciel, et al.
Pageof 65